Answers are grounded in this paper and cite their sources.
To the Editor: Madhi et al. (May 20 issue) 1 report on the efficacy of vaccination with the recombinant adenoviral vector encoding the spike protein antigen of SARS-CoV-2 (ChAdOx1 nCoV-19) against the SARS-CoV-2 B.1.351(or beta) variant lineage.They commented that in the ENSEMBLE study evaluating the efficacy of the Ad26.COV2.S vaccine, only patients with infection that was confirmed by polymerase-chain-reaction assay who had at least three signs or symptoms of Covid-19 were approved for end-point adjudication.The authors incorrectly concluded that the vaccine efficacy analyses excluded the majority of mild Covid-19 cases.However, all patients with mild or moderate cases of Covid-19 who had one or two symptoms did not require adjudication for confirmation as a case and were included in primary or secondary efficacy analyses, as detailed in the protocol.The Clinical Severity Adjudication Committee was established to independently assess, in a blinded manner, potential severe or critical cases of Covid-19, adjudicating all cases meeting the criteria for severe-critical disease and all cases meeting the criteria for moderate disease with at least three signs or symptoms to determine whether the case was severe-critical in their judgment.2 This focused process yielded blinded, independent confirmation of severecritical cases by clinical infectious disease experts and pulmonologists, ensuring the robustness and clinical relevance of this important end point.
No takes yet. Share an insight, caveat, or question.
Frank Struyf (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: